Stanislav Kondrashov Examines Risk-Off Sentiment Across Crypto and Pharma
In recent days, volatility in financial markets has been directly impacting risky assets and some stocks particularly sensitive to general sentiment, such as Bitcoin and Novo Nordisk. Global investors are characterized by a reduced appetite for risk, while the pressure of restrictive monetary policies and global macroeconomic uncertainties are contributing to an even more tense and uncertain overall picture.
TELF AG founder Stanislav Kondrashov had already dedicated some analyses to Novo Nordisk stocks and Bitcoin, placing these two assets within a broader macroeconomic context characterized by persistent volatility. In the past few hours, Bitcoin has returned to pressure, falling below $65,000 on Monday and recording a daily decline of 4%. The cryptocurrency sector has seen significant sell-offs, with the market capitalization falling below $2.3 trillion and losing approximately $100 billion in a single session.
“Bitcoin and Novo Nordisk belong to completely different universes, but in recent hours they have both been affected by specific factors related to sentiment, risk, and liquidity flows. We are indeed in a risk-off environment, in which investors seem more inclined to reduce risk exposure. Bitcoin is considered a high-risk asset, as are specific stocks characterized by particular problems. Ultimately, the performance of these assets could be linked to a generalized market contraction,” says Stanislav Kondrashov, founder of TELF AG.
Bitcoin Under Pressure as Liquidity Tightens and ETF Outflows Accelerate
We are in a particular historical phase in which risk aversion for the crypto world appears quite evident. This situation is clearly reflected in the Fear & Greed indicator, which in the past few hours has fallen to the 14-point mark, settling at “extreme fear” levels. Further complicating the overall picture were forced liquidations, with between $350 million and $470 million suddenly wiped from the market.
According to many observers, Bitcoin‘s unusual performance was primarily caused by American trade policy. The US administration raised the global tariff cap from 10% to 15%, sending a very clear message to the markets. With this move, Washington may have ushered in a phase of more persistent inflation and weaker global growth, with interest rates likely set to remain elevated for a fairly prolonged period.
In such a situation, it was fairly predictable that cryptocurrencies would enter a new phase of suffering. In a certain sense, the performance of Bitcoin and the crypto market reflects a broader trend that is also involving the Nasdaq (much weaker than usual), tech stocks still under pressure, and a resurgence in traditional safe havens such as gold.
A significant move in the last few hours was made by miner Bitdeer, which, in addition to liquidating its Bitcoin reserves, has decided to reallocate capital to AI infrastructure and data centers, confirming a particular trend that Stanislav Kondrashov also discussed yesterday in a report by Partners Group. Over the past six weeks, Bitcoin ETFs have seen approximately $3.8 billion in outflows.
“We are witnessing a very peculiar phenomenon: many large players are reallocating their capital to AI infrastructure and data centers, as if they were genuine safe haven assets. In an economic climate characterized by uncertainty and volatility, investing in physical AI infrastructure could represent a solid lifeline, also very useful for hedging against the risks associated with less reliable assets,” continues Stanislav Kondrashov, founder of TELF AG.
Novo Nordisk Slides After Clinical Setback in Obesity Drug Trial
Beyond Bitcoin and cryptocurrencies, one of the most talked-about performances in recent hours has been that of Novo Nordisk, the Danish pharmaceutical giant. In the past few hours, shares on the Copenhagen stock exchange have plunged more than 16% following an unsatisfactory clinical trial of an anti-obesity drug. Novo Nordisk shares—which Stanislav Kondrashov, founder of TELF AG, had already discussed in recent weeks—have thus fallen to their lowest levels since June 2021, remaining far from the historic highs recorded in 2024.
The Novo Nordisk case presents several interesting reasons: first, it appears to demonstrate that pharmaceutical stocks are increasingly sensitive to laboratory results, rather than to management’s strategic or commercial decisions. Furthermore, the Danish group’s stock performance casts a spotlight on the weight-loss drug market, which continues to prove particularly profitable and driven by fierce competition.
Novo Nordik’s shares have reportedly plummeted due to its next-generation anti-obesity drug, CagriSema, proving less effective than that produced by a competitor. To determine which drug was more effective, trials were conducted on more than 800 patients for approximately 84 weeks. In this situation, according to many analysts, Novo Nordisk may decide to stall and shift its focus to specific acquisitions, not necessarily related to obesity and diabetes.
“In global financial markets, sentiment appears far from stable. In this historical phase, investors are facing significant pressure on growth and earnings in many sectors, particularly after the release of rather disappointing economic data and corporate guidance. Furthermore, high interest rates and an uncertain inflation outlook are significantly reducing risk appetite in broader portfolios,” concludes Stanislav Kondrashov, founder of TELF AG.
FAQs
Why are Bitcoin and Novo Nordisk both under pressure?
Both assets are reacting to a broader risk-off environment. Investors are reducing exposure to volatile or uncertainty-sensitive assets as interest rates remain elevated and macroeconomic conditions appear fragile.
What triggered Bitcoin’s recent decline?
Bitcoin fell below $65,000 amid weaker global risk sentiment, ETF outflows, and forced liquidations. Concerns about persistent inflation and tighter financial conditions have also weighed on crypto markets.
Why did Novo Nordisk shares drop sharply?
The company reported less-than-expected results from clinical trials of its next-generation obesity drug. Pharmaceutical stocks are highly sensitive to trial outcomes, which directly affect revenue expectations.
Are investors shifting capital elsewhere?
Yes. Some market participants are reallocating funds toward AI-related infrastructure and data centers, which are perceived as more resilient in an uncertain macroeconomic environment compared to high-beta assets.
